Daniel Eisenman, PhD, RBP, SM(NRCM), CBSP

Executive Director, Biosafety Services, Advarra

Prior to joining Advarra, Daniel Eisenman served as Biosafety Officer at UNC Chapel Hill and the Medical University of South Carolina. Eisenman holds a PhD in Molecular Biology and Immunology from Augusta University, as well as various professional certifications in biological safety, including the Registered Biological Safety Professional (RBP) and Certified Biological Safety Professional (CBSP) certifications through the American Biological Safety Association (ABSA) and as a Specialist Microbiologist in Biological Safety (SM(NRCM)) through the American Society for Microbiology (ASM) National Registry of Certified Microbiologists (NRCM). He is also a devoted longtime educator, having taught microbiology at the undergraduate and graduate levels. Eisenman currently serves on the ABSA Owned Course Committee and is a regular speaker at clinical research conferences.

Latest Posts by Daniel Eisenman

Bacteriophage Therapy: A Promising Solution to Antibiotic Resistance

Antibiotic resistance is an emerging problem. Some have argued bacteria are developing antibiotic resistance faster...

Read More...

How Genetic Engineering Will Move Rare Disease Research at Warp Speed

Navigating research compliance often means addressing unseen challenges. Explore strategies to identify blind spots and...

Read More...

Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval

Rapid growth in gene therapy is expected to receive additional support as the Food and...

Read More...

How Centralized IBC Review Can Benefit Gene Therapy Research

Gene therapy research is at the forefront of a coming boom in the clinical setting....

Read More...

Reporting Unexpected Incidents to the IBC

When unexpected events occur during the conduct of a clinical trial, research personnel may wonder...

Read More...

IBC vs. IRB: What’s the Difference?

Gene therapy research requires both IRB and IBC oversight—while IRBs protect participants, IBCs ensure community...

Read More...

Safe Sharps Handling When Dispensing Investigational Products

Institutional biosafety committees (IBCs) frequently receive questions about the proper methodology for preparing a syringe...

Read More...

Clean Bench vs Biosafety Cabinet: What’s the Difference?

Institutional biosafety committees (IBCs) frequently receive questions about the proper type of hood for use...

Read More...
A decorative image for Regulatory Considerations Document for mRNA Research

mRNA Clinical Trials: Key Regulatory Considerations

Over the past two years, Operation Warp Speed brought mRNA-based vaccines into the spotlight, as...

Read More...

Does This Study Require IBC Review?

Gene therapy research is highly regulated due to associated risks, often leading to confusion among...

Read More...

mRNA and Its Role in Clinical Research

In the race to address the COVID-19 pandemic, researchers have worked tirelessly the past year...

Read More...

Does Warp Speed Vaccine Development and Testing Compromise Safety?

A common trope in sci-fi movies involves concerns about potentially smashing into uncharted objects while...

Read More...
Scroll to Top